Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System

Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, day 30 51% Improvement Relative Risk Mortality -59% late Famotidine  Yeramaneni et al.  Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? Retrospective 7,158 patients in the USA (February - May 2020) Lower mortality with famotidine (not stat. sig., p=0.22) c19early.org Yeramaneni et al., Gastroenterology, Feb 2021 Favorsfamotidine Favorscontrol 0 0.5 1 1.5 2+
Famotidine for COVID-19
26th treatment shown to reduce risk in October 2021
 
*, now with p = 0.00026 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use, but lower risk when there was pre-existing at-home use, without statistical significance in both cases.
Study covers remdesivir and famotidine.
risk of death, 51.0% lower, OR 0.49, p = 0.22, treatment 351, control 6,807, adjusted per study, with home use, multivariable, day 30, RR approximated with OR.
risk of death, 59.0% higher, OR 1.59, p = 0.09, treatment 410, control 746, adjusted per study, hospital use only, multivariable, RR approximated with OR, late treatment result.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yeramaneni et al., 28 Feb 2021, retrospective, USA, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.
This PaperFamotidineAll
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
Samrat Yeramaneni, Pratik Doshi, Kenneth Sands, Mandelin Cooper, Dax Kurbegov, Gregg Fromell
Gastroenterology, doi:10.1053/j.gastro.2020.10.011
P revious reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation. 1, 2 In 1 of these studies the authors proposed that famotidine inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease, 3-chymotrypsin-like protease, that is essential for breakdown of the immature SARS-CoV-2 protein particles that contribute to the inflammatory response seen in some COVID-19-infected individuals, 1 which in turn can lead to acute respiratory distress syndrome, multiorgan dysfunction, physiologic deterioration, and death. 3 In a global pandemic with a lack of US Food and Drug Administration-approved targeted therapeutic agents, identification and repurposing of well-established drugs with a proven track record of safety, affordability, and widespread availability are necessary. 4 The purpose of this study was to evaluate the reported protective effect of famotidine on mortality in hospitalized COVID-19 patients.
Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org and at https://doi.org/10.1053/ j.gastro.2020.10.011. Conflicts of interest The authors disclose no conflicts.
References
Dr, Luther, Boulevard, Suite 800
Freedberg, None, Gastroenterology
Iacus, None, Political Analysis
Mather, None, Am J Gastroenterol
Rogosnitzky, None, JMIR Public Health Surveill
Wang, None, Lancet
Zhou, None, Lancet
{ 'indexed': { 'date-parts': [[2021, 12, 23]], 'date-time': '2021-12-23T22:27:20Z', 'timestamp': 1640298440528}, 'reference-count': 7, 'publisher': 'Elsevier BV', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2021, 2, 1]], 'date-time': '2021-02-01T00:00:00Z', 'timestamp': 1612137600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [{'DOI': '10.13039/100016646', 'name': 'HCA Healthcare', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'gastrojournal.org', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Gastroenterology'], 'published-print': {'date-parts': [[2021, 2]]}, 'DOI': '10.1053/j.gastro.2020.10.011', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 10, 12]], 'date-time': '2020-10-12T05:38:45Z', 'timestamp': 1602481125000}, 'page': '919-921.e3', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 17, 'title': [ 'Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 ' 'Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System'], 'prefix': '10.1053', 'volume': '160', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1411-2359', 'authenticated-orcid': False, 'given': 'Samrat', 'family': 'Yeramaneni', 'sequence': 'first', 'affiliation': []}, {'given': 'Pratik', 'family': 'Doshi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kenneth', 'family': 'Sands', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mandelin', 'family': 'Cooper', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dax', 'family': 'Kurbegov', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gregg', 'family': 'Fromell', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1053/j.gastro.2020.10.011_bib1', 'doi-asserted-by': 'crossref', 'first-page': '1129', 'DOI': '10.1053/j.gastro.2020.05.053', 'volume': '159', 'author': 'Freedberg', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'key': '10.1053/j.gastro.2020.10.011_bib2', 'doi-asserted-by': 'crossref', 'first-page': '1617', 'DOI': '10.14309/ajg.0000000000000832', 'volume': '115', 'author': 'Mather', 'year': '2020', 'journal-title': 'Am J Gastroenterol'}, { 'key': '10.1053/j.gastro.2020.10.011_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1053/j.gastro.2020.10.011_bib4', 'doi-asserted-by': 'crossref', 'volume': '6', 'author': 'Rogosnitzky', 'year': '2020', 'journal-title': 'JMIR Public Health Surveill', 'DOI': '10.2196/19199'}, { 'key': '10.1053/j.gastro.2020.10.011_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1093/pan/mpr013', 'volume': '20', 'author': 'Iacus', 'year': '2012', 'journal-title': 'Political Analysis'}, { 'key': '10.1053/j.gastro.2020.10.011_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1569', 'DOI': '10.1016/S0140-6736(20)31022-9', 'volume': '395', 'author': 'Wang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1053/j.gastro.2020.10.011_bib7', 'year': '2020', 'journal-title': 'N\xa0Engl J Med'}], 'container-title': ['Gastroenterology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0016508520352495?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0016508520352495?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 3, 20]], 'date-time': '2021-03-20T07:51:40Z', 'timestamp': 1616226700000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2]]}, 'references-count': 7, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2021, 2]]}}, 'alternative-id': ['S0016508520352495'], 'URL': 'http://dx.doi.org/10.1053/j.gastro.2020.10.011', 'relation': {}, 'ISSN': ['0016-5085'], 'issn-type': [{'value': '0016-5085', 'type': 'print'}], 'subject': ['Gastroenterology', 'Hepatology'], 'published': {'date-parts': [[2021, 2]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match ' 'Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large ' 'Healthcare System', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Gastroenterology', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1053/j.gastro.2020.10.011', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2021 by the AGA Institute', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit